__timestamp | Alnylam Pharmaceuticals, Inc. | Pfizer Inc. |
---|---|---|
Wednesday, January 1, 2014 | 190249000 | 8393000000 |
Thursday, January 1, 2015 | 276495000 | 7690000000 |
Friday, January 1, 2016 | 382392000 | 7872000000 |
Sunday, January 1, 2017 | 390635000 | 7657000000 |
Monday, January 1, 2018 | 505420000 | 8006000000 |
Tuesday, January 1, 2019 | 655114000 | 8650000000 |
Wednesday, January 1, 2020 | 654819000 | 9405000000 |
Friday, January 1, 2021 | 792156000 | 13829000000 |
Saturday, January 1, 2022 | 883015000 | 11428000000 |
Sunday, January 1, 2023 | 1004415000 | 10679000000 |
Monday, January 1, 2024 | 1126232000 | 10930000000 |
Unveiling the hidden dimensions of data
In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Pfizer Inc. and Alnylam Pharmaceuticals, Inc. have demonstrated contrasting yet fascinating trajectories in their R&D investments.
From 2014 to 2023, Pfizer consistently allocated substantial resources to R&D, with expenditures peaking at approximately $13.8 billion in 2021. This represents a 65% increase from their 2014 spending, underscoring Pfizer's commitment to maintaining its leadership in the industry.
Conversely, Alnylam Pharmaceuticals, a smaller yet dynamic player, showcased a remarkable growth trajectory. Their R&D expenses surged by over 400% during the same period, reaching around $1 billion in 2023. This growth highlights Alnylam's aggressive pursuit of innovation, particularly in the field of RNA interference therapeutics.
These trends reflect the broader industry dynamics, where established giants and nimble innovators alike are investing heavily in the future of medicine.
Comparing Innovation Spending: Pfizer Inc. and Summit Therapeutics Inc.
Pfizer Inc. vs Jazz Pharmaceuticals plc: Strategic Focus on R&D Spending
R&D Insights: How Pfizer Inc. and TG Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Pfizer Inc. and Corcept Therapeutics Incorporated
R&D Insights: How Pfizer Inc. and Rhythm Pharmaceuticals, Inc. Allocate Funds
Pfizer Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Viridian Therapeutics, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Alnylam Pharmaceuticals, Inc. vs Blueprint Medicines Corporation: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Lantheus Holdings, Inc.
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Ascendis Pharma A/S
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.